News

Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option
Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...
STAT1d
Gilead’s CEO on the approval of a powerful new drug to prevent HIV
Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.
Pharmaceutical Technology on MSN1d
Gilead Sciences’ Yeztugo receives approval from US FDA for HIV
This is a historic day in the decades-long fight against HIV. Yeztugo is one of the most important scientific breakthrou ...
Stocktwits on MSN22h
Gilead Earns Analyst Praise As FDA Clears Yeztugo For Biannual HIV Prevention
Gilead Sciences garnered investor and analyst focus after the U.S. FDA approval of Yeztugo, or lenacapavir, the company’s ...
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® ...
BioPharma Dive2d
FDA approves twice-yearly shot of Gilead drug for HIV prevention
The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...
Daily Graphic8h
FDA approves powerful HIV prevention drug: What to know about Yeztugo
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...
PharmExec1d
FDA Approves Gilead’s Yeztugo as First Twice-Yearly Injection for HIV Pre-Exposure Prophylaxis
Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 ...
ConsumerAffairs13h
FDA approves twice-yearly injection for HIV prevention
FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...
Pharmabiz19h
Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection
Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...
Fierce Pharma2d
FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...
IFLScience on MSN8h
Revolutionary Drug That's “Closest Thing” To HIV Vaccine Gets FDA Approval
The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.